/
Other
Trial
132
Pipeline Programs↗
89
Active Trials↗
127
Companies Involved↗
Trial is a highly competitive landscape with 132 programs across 127 companies. The most active players are Mario Negri Institute for Pharmacological Research, Otsuka, Rare Thyroid Therapeutics International AB. 23 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical25
Phase 119
Phase 265
Phase 323
Approved
No programs
Analysis
Modality Breakdown
90%
Small molecule
111 of 124 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 124 classified programs, each share of the total. Modality classified for 100% of 132 pipeline programs.
Analysis
Trial Status
766
clinical trials
Completed505 · 66%
Unknown status71 · 9%
Terminated62 · 8%
Recruiting43 · 6%
Withdrawn34 · 4%
Active, not recruiting25 · 3%
Other26 · 3%
Clinical Trials
Trial Activity
766 trials
MIVetsCan: Cannabidiol (CBD)-Care Trial
Recruiting·—·Phase 2·NCT06213233·468 enrolled
SWIFT - SWIss Factor XIII Trial in PPH
Recruiting·—·Phase 4·NCT06481995·988 enrolled
Page 1 of 52
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)